BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37828627)

  • 41. Ferroptosis-associated DNA methylation signature predicts overall survival in patients with head and neck squamous cell carcinoma.
    Xu Y; Hong M; Kong D; Deng J; Zhong Z; Liang J
    BMC Genomics; 2022 Jan; 23(1):63. PubMed ID: 35042463
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Signal peptidase complex catalytic subunit SEC11A upregulation is a biomarker of poor prognosis in patients with head and neck squamous cell carcinoma.
    Hu C; Fan J; He G; Dong C; Zhou S; Zheng Y
    PLoS One; 2022; 17(6):e0269166. PubMed ID: 35653344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis.
    Li J; Liu J; Li J; Feng A; Nie Y; Yang Z; Zhang W
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11647-11659. PubMed ID: 37405477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma.
    Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P
    Front Immunol; 2022; 13():948042. PubMed ID: 36275737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
    Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
    Front Immunol; 2022; 13():991604. PubMed ID: 36685508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrated single-cell and bulk characterization of cuproptosis key regulator PDHB and association with tumor microenvironment infiltration in clear cell renal cell carcinoma.
    Wu J; Wang S; Liu Y; Zhang T; Wang X; Miao C
    Front Immunol; 2023; 14():1132661. PubMed ID: 37350959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
    Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
    Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
    Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
    Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prognostic value and immune landscape of a cuproptosis-related lncRNA signature in head and neck squamous cell carcinoma.
    Li YJ; Li HY; Zhang Q; Wei SL
    Front Genet; 2022; 13():942785. PubMed ID: 35942287
    [No Abstract]   [Full Text] [Related]  

  • 53. Construction of a novel cuproptosis-related gene signature for predicting prognosis and estimating tumor immune microenvironment status in papillary thyroid carcinoma.
    Wang L; Yao B; Yang J; Tian Z; He J
    BMC Cancer; 2022 Nov; 22(1):1131. PubMed ID: 36333684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
    Yan C; Niu Y; Ma L; Tian L; Ma J
    J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
    Huang Y; Gong P; Su L; Zhang M
    Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FAM3 Family as Prognostic Factors for Head and Neck Squamous Cell Carcinoma.
    Liao C; Wang Q; An J; Wang H; Xiao L; Long Q; Zhao H; Liu J; Guan X
    Comb Chem High Throughput Screen; 2023; 26(3):539-558. PubMed ID: 35538834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y; Zhang Q; Zhang H; Kong F
    Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
    Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
    Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
    Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
    Front Immunol; 2022; 13():933973. PubMed ID: 36045691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.